American Academy of Child & Adolescent Psychiatry

Exhibits Guide

Exhibit Dates: October 16–18, 2019



SPECIALIZED PRACTICE IS SAFE WITH US

WE PROTECT YOU

PRMS understands that each psychiatric specialty possesses its own unique set of challenges. Our medical malpractice insurance program is tailored with rates that reflect your specific risks and expert risk management materials relevant to your specialty.



VICTORIA WATKINS, RPLU ASSISTANT VICE PRESIDENT, INSURANCE SERVICES

Child and adolescent psychiatrists receive a 15% discount

Specialty-specific protection is just one component of our comprehensive professional liability insurance program.

When selecting a partner to protect you and your practice, consider the program that puts psychiatrists first. **Contact us today.**

Visit us at booth #312 during AACAP's 66th Annual Meeting!

More than an insurance policy

(800) 245-3333 | PRMS.com/Dedicated | TheProgram@prms.com



Actual terms, coverages, conditions and exclusions may vary by state. Insurance coverage provided by Fair American Insurance and Reinsurance Company (NAIC 35157). FAIRCO is an authorized carrier in California, ID number 3715-7. www.fairco.com.

GENERAL INFORMATION

.

Exhibit Hall Hours

Wednesday, October 16 Thursday, October 17 Friday, October 18 10:00 am-5:00 pm 10:00 am-4:00 pm 9:00 am-12:30 pm



Helen Beiser, MD, Art Show

Join us at the annual Helen Beiser, MD, Art Show in the Exhibit Hall. View the creative work of your colleagues, peers, and their families. Join the Artists on Thursday, October 17, from 12:30 pm-1:30 pm to learn about their art work.

The Art Show is coordinated by AACAP's Art Committee and Local Arrangements Committee.



Relax and Recharge Lounge

Relax in between programs and recharge your devices by visiting our Relax and Recharge Lounge in the Exhibit Hall!

Thank you to Supernus Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Ltd for their sponsorship of the Charging Stations.



Headshot Booth

Visit the Headshot Booth in the Exhibit Hall during Exhibit Hall hours and receive a complimentary headshot by a professional photographer! You will even get to leave the meeting with your headshot on a flash drive. The Headshot Booth is located across from booth #221, and will be done on a first-come, first-served basis.

Thank you to Tris Pharma, Inc. for their sponsorship of the Headshot Booth.



Fun Ribbons

Do you want to stand out at the meeting? Visit the Relax and Recharge Lounge to pick-up "fun ribbons" to add to your badge. Make sure to collect them all!



Wifi Access

There will be free wireless internet access throughout the meeting at the Hyatt Regency Chicago.

To access the wireless networks in the meeting space, please:



Select the **AACAP** network

You will immediately be prompted for a password, enter **AACAP2019**

You are ready to use the wifi!

ААСАР Арр

To download the AACAP Annual Meeting App, please go to the Apple iTunes store or the Android Marketplace and search for AACAP 2019. To log in, use the log in you used to register for the meeting.


WiFi Access network: AACAP password: AACAP2019

EXHIBIT HALL

Company/Organization Name	Booth
1-2-3 Magic	120
AACAP-PAC	
AACAP's Advocacy Committee and Psychopharmacology Committee	638
AACAP's Autism and Intellectual Disability Committee, Deaf/Hard of Hearing and Blind/Low Vision	
Committee, and Emergency Child Psychiatry Committee	639
AACAP's Ethics Committee, Research Committee, and Telepsychiatry Committee	540
Acadia Healthcare	534
Adlon Therapeutics L.P	240
AdvancedMD	101
American Board of Psychiatry and Neurology, Inc	628
American Professional Agency, Inc	
American Psychiatric Association	
American Psychiatric Association Publishing	
Arbor Pharmaceuticals, LLC	
Bay Area Clinical Associates (BACA)	
Carle Physician Group	
Catholic Charities of Baltimore	616
Centra Medical Group	640
Central Intelligence Agency	740
CFG Health Network	535
Children's Specialty Group	242
Community Psychiatry	435
Compulink Healthcare Solutions	313
Department of Psychiatry, University of Colorado Denver and Pediatric Mental Health Institute, Children's Hospital Colorado	716
Eagle Overlook Recovery	
for Adolescents	226
Eating Recovery Center/Insight Behavioral Health	621
Edward-Elmhurst Health	128
Elite DNA Therapy Services, LLC	720
Elsevier	434

Company/Organization Name	Booth
F. Hoffmann-La Roche Ltd	113
Fenix Health Science	
Geisinger	
Genoa Healthcare Telepsychiatry	201
Genomind, Inc	123
Guilford Press	107
Helen DeVos Children's Hospital	733
IACAPAP 2020	
Infinite Trading Inc	
innovaTel Telepsychiatry	
InSight Telepsychiatry	307
Integrated Psychiatric	
Consultants, P.A	326
Interior Health	529
Iris Telehealth	722
Ironshore Pharmaceuticals Inc	133
Kaiser Permanente—Southern California Permanente Medical Group	o 427
KSADS-COMP, LLC/Kennedy	
Krieger Institute	
LearnWell	
LifeStance Health	
LocumTenens.com	
MD Health Care Supplies	
Med Care Pharmaceuticals	
Medi Air Purifier	
Medical Billing Professionals	
Meridell Achievement Center	142
National Institute on Alcohol Abuse and Alcoholism (NIAAA)	
NeuroSigma, Inc	121
Newport Academy	328
NewYork-Presbyterian	207
Northwell Health	528
Orchard Place	839
Parkview Health/Parkview	
Behavioral Health	822
PCDH19 Alliance	826
Pine Rest Christian Mental	<i>a</i> =
Health Services	834

Company/Organization Name	Booth
PrairieCare Medical Group	209
Presbyterian Healthcare Services	823
Professional Risk Management Services, Inc. (PRMS)	312
ProMedica	122
Provider Solutions + Development	526
Robert Wood Johnson Barnabas Health	816
Rogers Behavioral Health	827
Rosecrance Health Network	
Sheppard Pratt Health System	206
Silver Hill Hospital	617
Skyland Trail	735
Southcentral Foundation	718
Sunovion Pharmaceuticals Inc	331
Supernus Pharmaceuticals, Inc	327, 126
Sutter Health Kāhi Mōhala	821
Takeda Pharmaceutical Company Ltd	340
The Department of Psychiatry and Behavioral Sciences at McGovern Mec School at The University of Texas Hea Science Center at Houston (UTHealth	lth
The Menninger Clinic	
The San Marcos Treatment Center	
The TOVA Company	
Tourette Association of America	
Traditions Behavioral Health	
Tris Pharma, Inc	
U.S. Department of State, Bureau of Medical Services	
UCSF-Fresno	
Universal Health Services, Inc	
Valant	
Vanderbilt Behavioral Health	
VCU Health	
WellSpan Philhaven	
Wiley	
Willow Springs Center	
Wolters Kluwer	
WPS	



1-2-3 Magic Booth #120

1935 Brookdale Road, Suite 139 Naperville, IL 60563 630.96.3900 www.123magic.com

1-2-3 Magic has helped millions of parents, teachers, and caregivers all over the world establish an effective, appropriate discipline system that helps children listen better and motivate themselves to behave well. Dr. Thomas Phelan is an internationally renowned expert in his field and has broken down the elements of effective parenting into an easy to understand program that can work for any family or in a classroom or caregiving scenario.

AACAP-PAC

3615 Wisconsin Avenue, NW Washington, DC 20016 202.966.7300

http://www.aacap-pac.com/

AACAP-PAC is the political action committee (PAC) of the American Association of Child and Adolescent Psychiatry (AACAP). AACAP-PAC's mission is to educate, support, and elect candidates for Congress who advocate for child and adolescent psychiatry and child mental health.

AACAP's Advocacy Committee and Psychopharmacology Committee Booth #638

3615 Wisconsin Avenue, NW Washington, DC 20016 202.966.7300 www.aacap.org

Wednesday, October 16: AACAP's Advocacy Committee is charged with helping to advance AACAP's overall advocacy and public policy agenda through focused activities and member support. This committee directs the development and activities of the Advocacy Liaison Network, AACAP's grassroots advocacy action group, assisting participating Regional Organizations as they advance their state advocacy priorities, and collaborates with AACAP's Department of Government Affairs to advance AACAP's federal legislative and regulatory agenda. In addition, the Advocacy Committee contributes to the implementation of AACAP's Legislative Conference and oversees the development of educational programming to build AACAP's advocacy workforce. AACAP members are invited to stop by the Advocacy Committee booth and learn how to lend your voice to advancing AACAP's advocacy priorities.

Friday, October 18: Officially established in 2016, AACAP's Psychopharmacology Committee grew out of a longstanding initiative of the Research Committee. Through products such as the Parents' Medication Guide series, Clinician's Toolbox, newsletter columns, and FDA Medication Tables, the Psychopharmacology Committee advocates for the safe and appropriate use of psychotropic medication and neurotherapeutics in children and adolescents. The committee strives to inform members about key issues regarding pediatric psychopharmacology and neurotherapeutics by developing extensive programming at the Annual Meeting and the Pediatric Psychopharmacology Update Institute.

AACAP's Autism and Intellectual Disability Committee, Deaf/Hard of Hearing and Blind/Low Vision Committee, and Emergency Child Psychiatry Committee

Booth #639

3615 Wisconsin Ave NW Washington, DC 20016 202.966.7300

www.aacap.org

Wednesday, October 16: The Emergency Child Psychiatry Committee dedicates itself to collaborating with child psychiatrists, pediatricians, and emergency medicine colleagues on establishing best practices and standards of care through research and education to further the care of patients and families experiencing a psychiatric crisis or emergency. Our mission is to shed more light on this critical aspect of psychiatric care and to create a more unified approach to the treatment of these young individuals. We hope to disseminate information and facilitate collaboration between various providers involved in the care of this vulnerable population.

Thursday, October 17: Stop by this booth to learn about the activities of AACAP's Autism and Intellectual Disability Committee and for information on advanced training opportunities in autism and intellectual disabilities across the nation.

Friday, October 18: Deaf/Hard of Hearing and Blind/Low Vision Committee— Come see and hear what your AACAP Deaf/Hard of Hearing, Blind/Low Vision Committee is doing, and you may even experience perception in a new way!

AACAP's Ethics Committee, Research Committee, and Telepsychiatry Committee Booth #540

3615 Wisconsin Ave NW Washington, DC 20016 202.966.7300 www.aacap.org

Wednesday, October 16: The Ethics Committee is an educational resource for the membership and components of AACAP. We welcome opportunities to collaborate with AACAP committees/members to develop ethics sponsored educational programs for the Annual Meeting. Through Ask Ethics, askethics@aacap.org, AACAP members can receive consultation on ethical dilemmas. More information and resources can be found on the AACAP website, https://www. aacap.org/AACAP/Member_Resources/ Ethics/Ethics_Committee/Home.aspx. The committee does not handle ethical complaints related to members.

Thursday, October 17: The Telepsychiatry Committee's mission is to assist AACAP members in developing knowledge, experience, and competency in synchronous and asynchronous telepsychiatry modalities. We develop member resources related to the practice, research, and policy implications of telepsychiatry to guide our members in establishing state of the art telepsychiatric care that adheres to AACAP's clinical and ethical standards.

Friday, October 18: Since 1999, AACAP's Research Committee has been responsible for the leadership and direction of the AACAP research programs, which are devoted to advancing medical science for the benefit of mentally ill youth. The Research Committee is responsible for administering the selection processes each year for AACAP's Junior Investigator Award and Pilot Research Awards. The committee also sponsors the Research Symposium, Research Institute, and the new Early Career Research Mentorship Colloquium at the Annual Meeting. Come meet some of AACAP's clinician scientists and learn how you can get involved to advance its research mission.

Acadia Healthcare Booth #534

6100 Tower Circle, Suite 1000 Franklin, TN 37067 615.861.7356 www.PracticeWithAcadiaHealth.com

Headquartered in Franklin, Tennessee, Acadia Healthcare was established in January 2005, to develop and operate a network of behavioral health facilities across the country. Acadia provides psychiatric and chemical dependency services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, outpatient clinics, and therapeutic schoolbased programs.

Adlon Therapeutics L.P. Booth #240

201 Tresser Boulevard Stamford, CT 06901 203.588.8690

www.adlontherapeutics.com

Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for ADHD and related disorders. Adlon is a subsidiary of Purdue Pharma L.P.

AdvancedMD Booth #101

500til #10

10876 S. River Front Parkway, Suite 400 South Jordan, UT 84095 800.825.0224

www.advancedmd.com

AdvancedMD strives to be the community of choice for independent mental health clinicians by delivering an integrated workflow and personalized service to ensure the health of every clinic and their patients. AdvancedMD Rhythm, the company's integrated suite of cloud solutions, includes practice management, EHR, telemedicine, intake forms, progress notes, treatment plans, group scheduling, and notes. They are all backed by expert practice advocates, serving 26,000 practitioners across 8,500 practices.

American Board of Psychiatry and Neurology, Inc. Booth #628

.

7 Parkway North Deerfield, IL 60015 847.229.6500

www.abpn.com

The American Board of Psychiatry and Neurology serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through its certification and maintenance of certification processes.

American Professional Agency, Inc. Booth #300

95 Broadway Amityville, NY 11701 877.740.1777

www.apamalpractice.com

American Professional Agency, Inc. (APA) is a leader in providing medical liability insurance for psychiatrists for over forty years and is the only program administrator sponsored by the American Academy of Child & Adolescent Psychiatry (AACAP) and endorsed by the American Psychiatric Association (APA). Allied World Assurance Company is an internationally recognized insurance company providing superior protection, top notch risk management services, and access to a hotline 24 hours a day.

American Psychiatric Association Booth #828

800 Maine Avenue, SW, Suite 900 Washington, DC 20024 202.559.3567

www.psychiatry.org

The American Psychiatric Association (APA) is an organization of psychiatrists working together to ensure effective treatment for all persons with mental illness, including substance use disorders (SUD). It is the voice and conscience of modern psychiatry. Its vision is a society that has available, accessible, and quality psychiatric diagnosis and treatment.

.

.

American Psychiatric Association Publishing Booth #727

800 Maine Avenue, SW Suite 900 Washington, DC 20024 202.609.7227

www.appi.org

American Psychiatric Association Publishing is the world's premier publisher of books, journals, and online products designed to advance the science of psychiatry and all child and adolescent psychiatrists.

Arbor Pharmaceuticals, LLC Booth #127

6 Concourse Parkway, Suite 1800 Atlanta, GA 30328 678.334.2420

www.arborpharma.com

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, neuroscience, hospital, and pediatric markets. Arbor currently markets over twenty NDA or ANDA approved products and also has several additional products in late-stage development. For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

Bay Area Clinical Associates (BACA) Booth #636

1175 Saratoga Avenue, Suite 14 San Jose, CA 95129 408.996.7950

www.baca.org

Bay Area Clinical Associates (BACA) is a physician-owned and operated organization offering evidence-based mental health services to youth and their families in the San Francisco Bay Area. BACA currently offers outpatient and intensive outpatient services in San Jose, Oakland, Menlo Park, and is exploring other sites as well.

Carle Physician Group Booth #820

611 W. Park Street Urbana, IL 61801 217.383.6945 https://carleconnect.com/

Carle is a vertically integrated health system serving more than 1.4 million people across east central Illinois. Named one of America's 50 Best Hospitals in 2019 by Healthgrades, the three-time Magnet® designated 433-bed regional hospital is home to the area's only Level I Trauma Center and Level III Perinatal Services. Carle Physician Group is physician led and includes more than 500 doctors in 80 specialties and subspecialties providing patient-focused, world-class care.

Catholic Charities of Baltimore Booth #616

2600 Pot Spring Road Timonium, MD 21093 667.600.3234 www.cc-md.org

Catholic Charities of Baltimore serves children and families, immigrants, individuals with intellectual disabilities, people living in poverty, and seniors in our 80 programs at 200 locations throughout Maryland. Designated as a *Baltimore Sun* Top Workplace, Catholic Charities is a dynamic, non-profit organization that encourages you to build a career where you make meaningful differences in the lives of Marylanders in need. Visit our booth to learn about our cutting-edge mental health programs and career opportunities with one of the largest psychiatry teams in Maryland.

Centra Medical Group Booth #640

2010 Atherholt Drive Lynchburg, VA 24501 434.485.2008

www.connectwithcentra.com

Centra Medical Group (CMG) is comprised of 450+ physicians and advanced practice providers and serves 250,000 central and southern Virginians. CMG offers an integrated healthcare system, including 4 hospitals, 3 long-term care facilities, 50+ physician practices, including primary care, medical, and surgical specialists.

.

Central Intelligence Agency Booth #740

Recruitment Center Washington, DC 20013 703.374.1999 www.cia.gov

.


The CIA is the premier agency responsible for providing global intelligence on the ever-changing political, social, economic, technological, and military environment. Here, your paramount goal and mission will be to protect the national security of the United States. Virtually any job you can imagine is available at the CIA—plus, some you can't even imagine.

CFG Health Network Booth #535

771 E. Route 70, Suite D-125 Marlton, NJ 08053 856.558.1774

www.cfghealthnetwork.com

CFG Health Network is a leader in the behavioral health care field, headquartered in southern New Jersey. CFG is a diverse company that provides psychiatric care to child residential programs, hospitals, and county correctional facilities, and operates their own outpatient clinics. CFG is continually seeking compassionate and dedicated psychiatrists to join their expanding network throughout New Jersey, Pennsylvania, and the Albany, New York area.



Children's Specialty Group Booth #242

811 Redgate Avenue Norfolk, VA 23507 757.668.6860 https://Csgdocs.com

Children Specialty Group (CSG) and Children's Hospital of The King's Daughters (CHKD) is seeking a child and adolescent psychiatrist to join our growing team. CSG and CHKD's vision for the future of the child and adolescent psychiatry practice involves over a \$50 million development of a med-psych inpatient unit, partial

hospital, IOP, and a psychiatric inpatient unit. The successful candidate will join a multi-disciplinary team of child and adolescent psychiatrists.

Community Psychiatry Booth #435

3835 N. Freeway Boulevard, Suite 100 Sacramento, CA 95834 916.974.4992

www.communitypsychiatry.com

Community Psychiatry is an outpatient, private practice group providing quality care to patients of all ages and diagnoses in over 30 locations throughout California, with anticipated expansion outside of California in 2020. We seek to create work settings that provide clinical autonomy, financial security, and freedom from administrative responsibilities of a private practice. Our providers focus on medication management with the option to practice psychotherapy.

Compulink Healthcare Solutions Booth #313

1100 Business Center Circle Newbury Park, CA 91320 800.456.4522

www.compulinkadvantage.com

A leader in all-in-one EHR and practice management solutions for behavioral health for 34 years, Compulink's Advantage SMART Practice[®] uses artificial intelligence to improve clinical and financial results.



Department of Psychiatry, University of Colorado Denver and Pediatric Mental Health Institute, Children's Hospital Colorado

Booth #716

13123 E. 16th Ave., Mail Stop B130 Aurora, CO 80045-7106 720.777.4097

https://medschool.cuanschutz.edu/ psychiatry

Behavioral health is important and our Department is leading efforts in developing comprehensive prevention and care. In collaboration with University of Colorado, University of Colorado Hospital, and Children's Hospital Colorado, and through major institutional investments, we are engaged in ambitious strategic planning and growth efforts to integrate clinical care, training, research, and policy. We are recruiting psychiatrists, psychologists, mental health professionals, and trainees to join our team. Please stop by booth #716 to learn more about us and job openings.

Eating Recovery Center/Insight Behavioral Health Booth #621

333 N. Michigan Ave. Suite 1900 Chicago, Illinois 60601 773.782.0184

www.ercinsight.com

Eating Recovery Center provides comprehensive eating disorder treatment for children and adolescents. In addition to providing eating disorder treatment, Insight Behavioral Health Centers, who has partnered with Eating Recovery Center, provides mood and anxiety disorder and obesity treatment for female and male adults and adolescents. We treat: Anorexia Nervosa, Food Intake Disorder (AFID), Binge Eating Disorder, Bulimia, Compulsive, Overeating, Diabulimia, Other Eating Disorders, and Mood & Anxiety Disorders.

Eagle Overlook Recovery for Adolescents Booth #226

45 Eagle Overlook Drive Dahlonega, GA 30533 706.867.0006

www.eagleoverlookrecovery.com

Eagle Overlook Recovery for Adolescents is a state licensed, Joint Commission Accredited ASAM Level 3.1 residential treatment program located in Dahlonega, Georgia. Our focus is treating adolescents aged 13 to *18 with a primary diagnosis of substance use disorders. (*18 years old if still in High School) Our facility is nestled on over 50 acres in the foothills of the Appalachian Mountains and oversees a private setting that is conducive to healing and self-discovery. We are a 4-6 week program with customized stays based on individualized care plans.

Edward-Elmhurst Healthcare Booth #128

801 S Washington Street Naperville, IL 60540 630.527.3207 eehealth.org

Edward-Elmhurst Health provides comprehensive healthcare at over 100 locations in the suburbs of Chicago. Our three hospitals are highly regarded for clinical excellence and patient-centered compassionate care. Our success has always been—and always will be—driven by our most talented, reliable, compassionate, and skilled people, who genuinely believe in delivering top quality care to our patients and their families.

Elite DNA Therapy Services, LLC Booth #720

6430 Plantation Park Court Fort Myers, FL 33912 239.223.2751 www.elitedna.us

Elite DNA is a behavioral health outpatient provider in Southwest Florida, with 8 location in 4 counties, and growing. We are looking to recruit some of the country's best and brightest behavioral health staff to help us meet the needs of the communities we serve.

Elsevier Booth #434

.

1600 John F. Kennedy Boulevard, Suite 1700 215.239.3795 Philadelphia, PA 19103 https://www.elsevier.com/

Elsevier is a global analytics business that helps institutions and professionals progress science, advance healthcare, and improve performance for the benefit of humanity.

F. Hoffmann-La Roche Ltd Booth #113

Bldg 1.11.NBH01 Basel, Basel-Stadt 4070 Switzerland 41.798659249 www.roche.com

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. There are no products to be promoted, we will focus on medical information and education which includes information about our investigational molecules.

Fenix Health Science Booth #143

1000 Parkwood Circle, # 900 Atlanta, GA 30339 404.550.9865

www.accentrate.com

Accentrate and Accentrate110 are nutritional supplements specifically formulated to address the nutritional deficiencies in children and adults with symptoms associated with ADHD.

Geisinger Booth #723

100 N. Academy Avenue Danville, PA 17822 717.745.6675 www.geisinger.org

Geisinger is a physician led health system comprised of approximately 30,000 employees, including nearly 1,600 employed physicians, 13 hospital campuses, two research centers, and a 583,000 member health plan. Geisinger is nationally recognized for innovative practices and quality care. Geisinger serves more than 3 million people in central, south-central, and northeast Pennsylvania and also in southern New Jersey with the addition of the National Malcolm Baldridge Award recipient

AtlantiCare, a member of Geisinger.

Genoa Healthcare Telepsychiatry Booth #201

1115 Broadway, Floor 10 New York, NY 10010 908.421.5374

www.genoatelepsychiatry.com

Genoa Healthcare is the nation's largest provider of outpatient telepsychiatry. As the telepsychiatry branch of Genoa Healthcare, we increase access to behavioral healthcare by building telepsychiatry programs that connect compassionate and skilled psychiatrists and APRNs with patients in underserved communities across the U.S. Genoa Healthcare Telepsychiatry serves behavioral health communities in over thirty-five states and provides care through over one hundred and twenty-five thousand annual appointments and counting.

Genomind Booth #123

2200 Renaissance Boulevard, Suite 100 King of Prussia, PA 19406 877.8955.8658

www.genomind.com

THE mental health company providing personalized medicine in pharmacogenetic testing. We look at 24 genes associated to mental health disease. Clinicians use the results to determine a treatment path with increased odds of efficacy and response by avoiding adverse effects.



Make a difference in a child's life with Presbyterian Behavioral Health.

Dedicated to improving the health of our community, Behavioral Health at Presbyterian offers treatment for lasting recovery from substance abuse, behavioral health conditions and psychiatric emergencies. Our program includes two adult units (30 beds), one child/adolescent inpatient unit (15 beds), a multidisciplinary outpatient clinic, intensive outpatient treatment, emergency and consultative services and behavioral medicine services embedded in primary care.

We are seeking a board certified or board eligible child and adolescent psychiatrist to join our outpatient practice in Albuquerque, New Mexico. Our psychiatrists work as a team with our psychologists, therapists, psychiatric social workers and registered nurses to deliver a full continuum of services.

Presbyterian offers competitive salaries with relocation allowance, day-one comprehensive benefits packages, CME allowance, wellness programs and more.

To learn more about Presbyterian or apply, contact Susan Camenisch at scamenisc@phs.org or (505) 923-8718.

AA/EEO/VET/DISABLED/NMHRA. PHS is committed to ensuring a drug-free workplace. PRESBYTERIAN www.phs.org/careers

Guilford Press Booth #107

370 7th Avenue, Suite 1200 New York, NY 10001 212.431.9800 www.guilford.com

New titles from Guilford include Bukstein, Treating Adolescents with Substance Use Disorders, Braaten, The Child Clinician's Report-Writing Handbook, 2e, Pollak, Self-Compassion for Parents, and Prinstein, Treatment of Disorders in Children and Adolescence, 4e.

Helen DeVos Children's Hospital Booth #733

100 Michigan Street, NE Grand Rapids, MI 49503 616.486.6683

www.helendevoschildrens.org

The growing pediatric behavioral health team at Helen DeVos Children's Hospital strives to care for the whole child, which includes their mental health, physical health, personal, family, school, and community needs. Our experts utilize a multidisciplinary and comprehensive approach to diagnosing and determining the root of the child's problem; then, they take a biological, psychological, and social approach to create a personalized treatment plan for each child. Proper diagnosis and treatment of symptoms and disorders can change a child's and their family's future.

IACAPAP 2020 Booth #838

20 Bendeemer Road #04-02 Singapore 339914 www.iacapap2020.org/

The 24th World Congress of the IACAPAP will be held from 20–23 July 2020 in Singapore. The Congress supports IACAPAP in it's work of facilitating improvements in mental health of children, adolescents & their families in communities around the world. The Congress will discuss scientific research, theoretical developments, clinical practice, policy & advocacy. The 2020 Congress is proudly organized by the IACAPAP, Institute of Mental Health Singapore & a network of Singapore agencies & hospitals.

Infinite Trading Inc Booth #309

1810 E. Sahara Ave, Suite 1482 Las Vegas, NV 89104 702.250.1683 EMS Technology

innovaTel Telepsychiatry Booth #215

900 State Street, Suite 203B Erie, PA 16501 866.492.7597 www.innovatel.com

With a growing demand for behavioral health services and a shortage of providers, access to care is challenging. Telepsychiatry is a solution to bridge this gap in care. innovaTel has a nationwide network of child and adolescent psychiatrists, nurse practitioners, and licensed clinical social workers that connect to organizations virtually through telemedicine.

InSight Telepsychiatry Booth #307

765 Route 70 E., Bldg A Marlton, NJ 08053-2341 973.885.5750

www.insighttelepsychiatry.com

InSight is the leading national telepsychiatry service provider organization with a mission to transform access to behavioral healthcare through innovative applications of technology. InSight has two decades of experience, serves hundreds of organizations, and is uniquely positioned to offer scalable telepsychiatry services in settings across the continuum of care.

Integrated Psychiatric Consultants, P.A. Booth #326

.

10801 Mastin Boulevard Building 84, Suite 510 Overland Park, KS 66210 913.744.5877

www.integrated-pc.com

Integrated Psychiatric Consultants (IPC) is group psychiatric practice with flexible opportunities to work in various practice settings including inpatient, PHP/IOP, residential, or outpatient programs in adult, child and adolescent, and geriatric programs. We are physician owned and operated. IPC is a full-service psychiatric treatment provider which offers end to end solutions to meet the needs of various organizations. IPC can accommodate J-1& H-1 Sponsorships.

Interior Health Booth #529

.

505 Doyle Avenue Kelowna, British Columbia V1Y3N8 Canada 250.469.7045 www.interiorhealth.ca

Interior Health is a publicly funded health authority in the province of British Columbia (BC), Canada, developing the future of health care through innovation and professional development.

We are currently recruiting psychiatrists to join our dedicated teams in our communities. Come enjoy a rewarding career opportunity in either an urban or rural community. With spectacular scenery and unlimited leisure activities, the southern interior of BC is the perfect place to advance your medical career.

Iris Telehealth Booth #722

114 West 7th Street, Suite 900 Austin, Texas 78701 512.522.9854

www.iristelehealth.com

Iris Telehealth is a telepsychiatry provider organization made up of the highest quality psychiatrists and psychiatric nurse practitioners. Our mission is to provide underserved communities with access to the best mental health specialists and prescribers. We are owned and operated by doctors who understand what patients need and have earned a reputation for providing outstanding customer service. Iris values building strong professional relationships with our partners and their staff.

Ironshore Pharmaceuticals Inc. Booth #133

430 Davis Drive, Suite 250 Morrisville, NC 27560 877.938.5766

www.ironshorepharma.com

Ironshore Pharmaceuticals Inc. is a pharmaceutical company whose mission is to develop innovative, patientcentric treatment options using the proprietary DELEXIS® drug delivery technology to improve the lives of patients and caregivers. Ironshore is a leader in the research, development, and commercialization of novel treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD), which leverage this unique technology.

Kaiser Permanente—Southern California Permanente Medical Group Booth #427

393 East Walnut Street Pasadena, CA 91188 800.541.7946

https://scpmgphysiciancareers.com

Within the Permanente Medical Groups physicians find recognition, stability, opportunity, and independence. Driven by the needs of our members and built on a platform in which medical decisions are made by physicians, each of our locations are able to self-manage the resources necessary for the delivery of excellent patient care.

Mark Your Calendar for AACAP's Future Meetings!

Pediatric Psychopharmacology Update Institute

January 31–February 1, 2020 Westin Long Beach Long Beach, CA

Douglas B. Hansen, MD, 45th Annual Update Course March 30–May 8, 2020 Online Course

AACAP Legislative Conference and Assembly Meeting

April 2–4, 2020 Hyatt Regency Washington on Capitol Hill Washington, DC

67th Annual Meeting

October 19–24, 2020 Hilton San Francisco Union Square and Hotel Nikko San Francisco San Francisco, CA

68th Annual Meeting

October 25–30, 2021 Hyatt Regency Atlanta and Atlanta Marriott Marquis Atlanta, GA

69th Annual Meeting

October 17–22, 2022 Metro Toronto Convention Centre Toronto, Ontario, Canada

70th Annual Meeting

October 23–28, 2023 New York Hilton Midtown and Sheraton New York Times Square Hotel New York, NY

KSADS-COMP, LLC/Kennedy Krieger Institute Booth #308

1741 Ashland Avenue Baltimore, Maryland 21205 443.923.5953

www.ksads-comp.com

The K-SADS is the most widely used and well validated child diagnostic interview. There are now three web-based versions of the K-SADS: a clinician-administered; a youth self-administered; and a parent selfadministered version. The clinician KSADS-COMP shows utility not only for research, but also in clinical practice, with self-report pre-interview ratings that streamline administration. The self-administered KSADS-COMPs have utility in large-scale studies, schools, emergency departments, and in telehealth to address the critical shortage of mental health specialists.

.

LearnWell Booth #432

2 Main Street, Suite 2A Suite 2A Plymouth, MA 02360 877.732.9101 https://learnwelleducation.com

LearnWell helps hospitals and treatment centers to reduce operating costs while providing high quality, individualized education programs for school-age patients. Since 1995, we have worked closely with facilities and school districts, to help normalize the patient experience. For more information, visit our website at www.learnwelleducation. com or contact us at info@ learnwelleducation.com or 877.732.9101.

LifeStance Health Booth #243

10655 NE 4th Street, Suite 901 Bellevue, WA 98004 206.279.8506 www.lifestance.com

LifeStance is a national provider of behavioral healthcare services with operations across the country. Founded in 2017, LifeStance brings together psychiatrists, psychologists, nurse practitioners, clinical counselors and social workers across the country to provide comprehensive mental health treatment services for patients of all ages. Every LifeStance team member is dedicated to providing the utmost in compassionate care and treatment to serve the specific needs and concerns of each individual patient.

LocumTenens.com Booth #623

2575 Northwinds Parkway Alpharetta, GA 30009 800.562.8663

www.locumtenens.com

The need has never been greater to connect great clinicians and great healthcare facilities. That's what we do. Every day. We're LocumTenens.com. We connect clients and clinicians to take care of patients. How do we do it? By doing it better than everyone else. Whether you're looking for a locum tenens job or locum tenens coverage, our experienced agents have the specialized knowledge, know-how, and personal relationships to take care of you and your search.

MD Health Care Supplies Booth #129

Unite 37 Bates Industrial Estate Church Road London , UK RM30UH +44.797.338.3667

Med-Care Pharmaceuticals Booth#227

8383 Wilshire Boulevard Beverly Hills, CA 90211 619.292.1479 https://www.medcarepharma ceuticals.com/

Med Care Pharmaceuticals is a researchbased pharmaceutical company that discovers and develops innovative medical solutions. Med Care Pharmaceuticals is focused on developing high-quality (OTC) over-the-counter medications and dermatology products.

Medi Air Purifier

Booth #840

1717 Harris Hawk Road Orlando, FL 32837 847.609.0593

www.mediairpurifier.com

Medical Billing Professionals Booth #222

P.O. Box 560

Royersford, PA 19468 610.792.8819 www.mbpros.com

MBPros has been serving behavioral health

providers nationwide since 1995, with fees as low as \$1.75 per claim. Stop by our booth for our Show Special with up to 4 months free and 20% off our prepayment rates. We can submit your claims, verify benefits and eligibility, follow up on any outstanding or denied claims, and post all payments from insurance and your patients. Using a service charging a percentage? Ask if you can save with MBPros.

Meridell Achievement Center Booth #142

12550 West Highway 29 P0 Box 87 Liberty Hill, TX 78642 512.517.2774

www.meridell.com

Meridell Achievement Center (MAC) is a residential treatment center for 11-17 year old males/females, specializing in neuropsychiatry and psychiatry. Key diagnoses/disorders include: depression, cluster B, disruptive mood dysregulation disorder (DMDD), intermittent explosive, bipolar (BD), anxiety (AD), attention-deficit/ hyperactivity disorder (ADHD), posttraumatic stress disorder (PTSD), oppositional defiant disorder (ODD), and conduct disorder (CD). Learning professionals include: six child and adolescent psychiatrists; pediatric neurologist; neuropsychologist, psychologist; nursing care 24/7 and evidence-based therapy, informed by DBT, cognitivebehavioral therapy (CBT), and systemic family therapy. We accept Tricare worldwide.

National Institute on Alcohol Abuse and Alcoholism (NIAAA) Booth #717

P.O. Box 10686 Rockville, MD 20849-0686 888.696.4222 www.niaaa.nih.gov

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) exhibit highlights the importance of alcohol research, prevention, and treatment for maintaining the health of the individual, the family, and the nation. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) booth features publications appropriate for the public, research findings for professionals and policy makers, and research grant opportunities available for biomedical and social science researchers.

NeuroSigma, Inc. Booth #121

10960 Wilshire Boulevard, Suite 1910 Los Angeles, CA 90024 310.479.3100

www.neurosigma.com

The Monarch eTNS System by NeuroSigma is the only FDA-cleared medical device for the treatment of pediatric ADHD, without the need for daily medication. The therapeutic pulses stimulate the branches of the trigeminal nerve, which activates the neural pathway to other parts of the brain thought to be involved in ADHD. It is intended to be used in the home under supervision of a caregiver at night while the child is sleeping. Learn about the clinical study and how to prescribe at booth 121.

Newport Academy Booth #328

811 N. Ranch Wood Trail Orange, CA 92869 866.367.8336 www.newportacademy.com

Newport Academy is a series of evidencebased healing centers for adolescents, young adults, and families struggling with mental health illnesses, eating disorders, and substance use disorder (SUD). We offer a compassionate, family systems approach, providing gender specific, holistic programs that encompass clinical therapy, academic support, and experiential practices.

NewYork-Presbyterian Booth #207

466 Lexington Avenue, Box 18 New York, NY 10017 212.746.9723

www.nyp.org

NewYork-Presbyterian is one of the most comprehensive academic medical centers in the world, with leading specialists in psychiatry and psychology. Our facilities throughout New York City and Westchester County provide a wide variety of outpatient and inpatient mental health and substance abuse services for pediatric, adolescent, adult, and geriatric patients. Our dedicated staff works diligently to provide patients and visitors the highest quality, most compassionate care, and service.

Northwell Health Booth #528

600 Community Drive Manhasset, NY 11030 516.823.8022

www.northwell.edu

Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals and over five hundred and fifty outpatient practices. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees, over fifteen thousand nurses, and nearly three thousand and four hundred physicians, including nearly two thousand and seven hundred members of Northwell Health Physician Partners—are working to change health care for the better.

Orchard Place Booth #839

2116 Grand Avenue Des Moines, IA 50312 515.246.3514

www.orchardplace.org

Orchard Place is the oldest locally-based charity in Des Moines providing mental health treatment for lowa's kids. Our inpatient, outpatient, and community programs serve nearly 10,000 children from birth to age 22 annually. Through our three branches of service, we contribute to the community's well-being by serving the mental health, substance abuse, educational, and juvenile justice needs of youth. These services are delivered by compassionate and highly trained physicians, physician assistants, nurses, therapists, residential treatment staff, and psychologists.

Parkview Health/Parkview Behavioral Health Booth #822

10501 Corporate Drive Fort Wayne, IN 46845 260.266.2521

.

www.parkview.com

Parkview Behavioral Health (PBH) is a seeking child and adolescent psychiatrists for both inpatient and outpatient settings. PBH is part of Parkview Health, a not-forprofit, community-based health system serving a northeast Indiana and northwest Ohio population of more than 895,000. With more than 12,000 employees, Parkview Health is the region's largest employer.

PCDH19 Alliance Booth #826

926 A #212 Diablo Ave Novato, CA 94947 925.209.6307 www.pcdh19info.org

Our mission is to improve the lives of children and families affected by PCDH19 epilepsy. The PCDH19 Alliance focuses on raising and directing funds to scientific research with the goal of finding better, more effective treatments and, ultimately, a cure. We're also here to provide information and support to affected families, assist research efforts, and ensure that no family suffers without a diagnosis and the best medical treatment.

.

Pine Rest Christian Mental **Health Services** Booth #834

300 68th Street SE Grand Rapids, Michigan 49548 616.558.5959

www.Pinerest.org

Pine Rest, a nonprofit organization founded in 1910 in Grand Rapids, Michigan, is the leading behavioral health system in the region offering a full continuum of care for all ages. As a Department of Psychiatry with Michigan State University's College of Medicine, there is faculty appointment, residency training program, and research. Pine Rest offers diverse psychiatric career opportunities; one employer, endless opportunities.

PrairieCare Medical Group Booth #209

9400 Zane Avenue North Brooklyn Park, MN 55443 612.274.7404

www.prarie-care.com

PrairieCare is an inpatient psychiatric hospital with several free-standing clinics/ partial hospital programs in the Twin Cities (Minnesota), employing approximately half of the child and adolescent psychiatrists in the state. We offer clinic, IOP, PHP, hospitalization, and residential care for children and adolescents. We are exhibiting to recruit psychiatrists.

Presbyterian Healthcare Services Booth #823

PO Box 26666 Albuquerque, NM 87125 505.923.5567 www.phs.org

Presbyterian Healthcare Services is a locally owned, not-for-profit healthcare system based in Albuquerque, New Mexico. Our integrated healthcare system includes nine hospitals in eight New Mexico communities, a medical group, multispecialty clinics and a statewide health plan. We have proudly been providing care to New Mexicans since 1908. The Presbyterian Medical Group employs more than 950 primary care and specialty providers and we are growing.

Professional Risk Management Services, Inc. (PRMS) Booth **#312**

1401 Wilson Boulevard, #700 Arlington, VA 22209 703.907.3851

www.Prms.com

PRMS® manages The Psychiatrists' Program[®], a full-service medical professional liability insurance program for behavioral healthcare providers unparalleled in its risk management expertise, aggressive defense strategies, and specialized comprehensive policy. Our impressive 95% retention rate illustrates our dedication to client satisfaction, our quality of service, and our extremely skilled and responsive staff. License defense coverage up to \$150,000, and telepsychiatry and forensic coverage included at no cost. * Premium discounts up to sixty percent. *May vary by state.

ProMedica Booth #122

100 Madison Ave Toledo, OH 43604 567.585.9600

www.promedica.org

ProMedica is a mission-based, not-forprofit integrated healthcare organization headquartered in Toledo, Ohio. It serves communities in 30 states. The organization has more than 70,000 employees, 13 hospitals, 2,700 physicians and advanced practice providers with privileges. Driven by its mission to improve your health and well-being, ProMedica has been nationally recognized for its advocacy programs and efforts to address social determinants of health.

Provider Solutions + Development Booth #526

1201 NE Lloyd Boulevard, Suite 500 Portland, OR 97232 844.874.7742 www.psdrecruit.org

Founded within Providence St. Joseph Health, Provider Solutions and Development is a not-for-profit clinical career navigation organization. For over 20 years, we've helped thousands of physicians and providers achieve their practice potential. Our growing network of health system partners offers innovative care models, diverse practice locations across the nation, and a shared culture of service.

AACAP JobSource

AACAP is pleased to offer JobSource, an advertising and recruiting tool to assist AACAP members and related experts looking for new career opportunities, and to help employers find the most qualified children's mental health professionals.

JobSource is simple and easy to use. Get to everything you need with just a few clicks. Visit us online at www. aacap.org and find JobSource under Quick Links or Member Resources.

Questions? Please contact Reilly Polka, Communications Manager, at *rpolka@aacap.org*.



Clinical Excellence in Adolescent Treatment. Compassionate Care.

The Adolescent Program at Silver Hill

provides specialized treatment for teens ages 13 – 17, with psychiatric issues or co-occurring substance use disorders

Psychiatry at our Core

Did you know that, at Silver Hill, every patient's care is coordinated by a full-time, board-certified child and adolescent psychiatrist? In fact, we provide psychiatric coverage 24/7.

Expert care all along the way

Our continuum of care model supports progress and recovery at every stage, including:

- inpatient
- transitional living
- intensive outpatient
- family support

At the center for adolescents we treat:

- depression
 anxiety disorders
- eating disorders
- self-harm
- oppositional defiant disorder
- co-occurring substance abuse

disorders Consider us your partner in care

Collaboration and communication are inherent in what we do as your partner in care. We work collaboratively with you and keep you informed, so that together, we can achieve the best outcomes for your patients.

To learn more about the benefits of collaborating with us, give us a call at 866.542.4455 or visit silverhillhospital.org



Robert Wood Johnson Barnabas Health Booth #816

95 Old Short Hills Road Livingston, New Jersey 07052 862.236.0720

https://www.rwjbh.org

RWJBarnabas Health is the most comprehensive health care delivery system in New Jersey, treating over 3 million patients a year. It is also New Jersey's second largest private employer—with more than 32,000 employees, 9,000 physicians and 1,000 residents and interns—and routinely captures national awards for its outstanding quality and safety.

Rogers Behavioral Health Booth #827

34700 Valley Road Oconomowoc, WI 53066 800.767.4411

www.rogersbh.org

Rogers Behavioral Health is a leading, nonprofit provider of mental health and addiction services. Rogers offers evidence-based treatment for adults, children, and teens with depression and mood disorders, eating disorders, addiction, obsessive-compulsive disorder (OCD) and anxiety disorders (AD), posttraumatic stress disorder (PTSD), and mental health disorders in children on the autism spectrum. Rogers provides services throughout Wisconsin as well as in Chicago, Minneapolis, Nashville, Philadelphia, Tampa, Miami, San Diego, and San Francisco.

Rosecrance Health Network Booth #739

1021 North Mulford Road Rockford ,IL 61107 815-391-1000

www.rosecrance.org

Rosecrance is recognized as a leading provider of services for people with substance use and mental health disorders. We currently offer services at more than 60 sites across Illinois, Wisconsin, and lowa. Rosecrance served more than 50,000 children, teens, adults, and families in the past year. To learn more about Rosecrance and view our facilities, visit rosecrance.org.

Sheppard Pratt Health System Booth #206

6501 North Charles Street Baltimore, MD 21204 410.938.3000

www.Sheppardpratt.org

Sheppard Pratt Health System is the largest private, non-profit provider of mental health, substance use, developmental disability, special education, and social services in the country. Sheppard Pratt provides services across a comprehensive continuum of care, spanning both hospital and communitybased resources. Since 1853, Sheppard Pratt has been innovating the field through research, best practice implementation, and a focus on improving the quality of mental health care on a global level.

Silver Hill Hospital Booth #617

208 Valley Road New Canaan, CT 06840 203.801.3445

www.silverhillhospital.org

Founded in 1931, Silver Hill Hospital is a nationally recognized non-profit psychiatric hospital located 50 miles north of New York City. Silver Hill provides evidence-based treatment for adolescents with psychiatric and addictive disorders. Silver Hill provides a full continuum of care; acute inpatient services, residential transitional living, and an intensive outpatient program.

Skyland Trail Booth #735

1961 N. Druid Hills Road NE Atlanta, GA 30329 866.528.9593

.

www.skylandtrail.org

Located in Atlanta, the Skyland Trail adolescent residential treatment program treats teens ages 14 to 17 struggling with depression, bipolar disorder, anxiety disorders, and obsessive-compulsive disorder. Our evidence-based residential program helps adolescents develop the resilience and life skills needed to navigate academic challenges and changing social and family relationships. Family-focused programming helps parents learn new strategies to support their teens as they prepare to leave home for college or life's next adventure. Learn more at skylandtrail.org.

Southcentral Foundation Booth #718

4501 Diplomacy Drive Anchorage, AK 99508 907.947.4454

www.southcentralfoundation.com

Southcentral Foundation is the largest Alaska Native owned health care system in the state and provides a variety of services to nearly 65,000 Alaska Native and American Indian people. Our internationally recognized, relationship-based model of care was created from our belief that the journey to wellness is a partnership and a responsibility shared between the patient and provider, that extends beyond the individual, to the family, the community, and to the world in which we live.

Sunovion Pharmaceuticals Inc. Booth #331

84 Waterford Drive Marlborough, MA 01752 732.530.3363 www.sunovion.com

Sunovion is a global biopharmaceutical

company focused on the innovative application of science and medicine to help people with serious medical conditions. With patients at the center of everything it does, Sunovion has an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions. Visit us at www.sunovion.com.

Supernus Pharmaceuticals, Inc. Booth #327

1550 East Gude Drive Rockville, MD 20850 240.818.4143

www.supernus.com

Supernus Pharmaceuticals, Inc. is focused on developing and commercializing products for the treatment of central nervous system disorders, including epilepsy, migraine, attention-deficit/ hyperactivity disorder (ADHD), impulsive aggression, and depression. Our extensive expertise in product development has been built over the past 25 years—primarily as a US subsidiary of Shire and starting late 2005 as Supernus—fueling the success of more than 10 widely recognized products, including multiple products for ADHD: Adderall XR[®], Intuniv[®], and Mydayis[®].

Sutter Health Kāhi Mõhala Booth #821

91-2301 Fort Weaver Road Ewa Beach, HI 96706 808.677.2805 www.Sutterhealth.org/kahi

Sutter Health Kāhi Mōhala offers innovative, quality, and effective behavioral health services and treatment programs that are designed to help individuals reach their full potential, where children and adolescents successfully integrate into home and school, and adults transition to their level of independent or supported living.

Takeda Pharmaceutical Company Ltd Booth #340

One Takeda Parkway Deerfield, IL 60015 224.554.6500 https://www.takeda.com

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, valuesbased, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing better health and a brighter future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: oncology, gastroenterology (GI), rare diseases, and neuroscience. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

The Department of Psychiatry and Behavioral Sciences at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth)

Booth #533

1941 East Road Suite 2100 Houston, Texas 77054 713.486.2525 https://med.uth.edu/psychiatry/about-

us/welcome/

UTHealth Houston McGovern Medical School's child psychiatrists are leading Houston in the care of children and families through our work in education, clinical care, and research. Our affiliated inpatient hospital will become the largest U.S. teaching psychiatric hospital by 2021. Our telemedicine division services the state hospital system, schools, and primary care clinics across Texas. We work alongside primary care clinicians in over 20+ integrated care clinics. We also offer specialized care in our clinical research centers related to mood, addiction, trauma, and autism.

The Menninger Clinic Booth #527

12301 S Main Street Houston, TX 77035 713.275.5400

www.menningerclinic.edu

The Menninger Clinic in Houston, Texas, provides transformational diagnosis and treatment for adolescents and adults with severe psychiatric and co-occurring conditions. Inpatient treatment includes separate units for adolescents, adults, professionals, and psychiatric assessment and stabilization. There are also programs for brain health and Menninger 360 and a community reintegration program called Pathfinder. Menninger is affiliated with Baylor College of Medicine.

The San Marcos Treatment Center Booth #626

120 Bert Brown Road San Marcos, TX 78666 512.213.8643

www.sanmarcostc.com

San Marcos Treatment Center is a psychiatric residential treatment center located on sixty-five acres in the Texas Hill Country, 25 miles south of Austin and 50 miles north of San Antonio. With an abundance of trees and wildlife, this idyllic setting provides a healthy environment for children and adolescents. Our highly specialized intensive residential programs provide 24-hour care to a broad spectrum of girls and boys ages 6–17 with IQs of 50 and above.

The TOVA Company Booth #306

.

3321 Cerritos Avenue Los Alamitos, CA 90721 360.661.2899

www.thetovacompany.com

The Test of Variables of Attention (TOVA) is a Food and Drug Administration (FDA) cleared, state of the art CPT used in the assessment of attention disorders, including attention-deficit/hyperactivity disorder (ADHD). The Test of Variables of Attention (TOVA) is language and culture free, sufficiently long to measure vigilance, and includes visual and auditory tests. Specially designed hardware addresses the timing delays inherent in other computerized tests. Normed four to over eighty by gender. ADHD comparison score and performance validity for ages 17 and up. Easy to read report. Free support services.

Tourette Association of America Booth #738

42-40 Bell Blvd Bayside, NY 11361 718.224.2999 www.Tourette.org

Founded in 1972, the Tourette Association of America is dedicated to making life better for all individuals affected by Tourette and tic disorders. The only nationwide organization serving this community, the Association works to raise awareness, fund research, and provide ongoing support. The Tourette Association directs a network of 32 Chapters and over 80 support groups across the country. For more information on Tourette and tic disorders, call 1.888.4.TOURET, visit www. tourette.org, and on Facebook, Twitter, Instagram and YouTube.

Traditions Behavioral Health Booth #634

1580 First Street Napa, CA 94559 707.258.8757 https://tbhcare.com/

"I started TBH in 1996, to create a company that fostered for psychiatrists a principle focus on patient care. I wanted to create a practice environment focused on outcome, not on time-restricted doctor visits. I wanted to provide a haven from bureaucracy, third party billing, and the administrative challenges that confront doctors. By partnering with select hospitals and clinics, we create a dynamic synergy between treatment facility and physicians and nurse practitioners to better serve our consumers."

–Gary A. Hayes, PhD, President, Founder, Owner

Tris Pharma, Inc. Booth #221

2031 US 130 Monmouth Junction, NJ 08852 732.823.7731

www.trispharma.com

Tris Pharma, Inc. is a specialty pharmaceutical company focused on neurobehavioral disorders in pediatric and adult patients. Tris has pioneered extendedrelease (ER) formulations in delivery of sustained release in liquid, chewable/ODT, and other unique dosage forms.

U.S. Department of State, Bureau of Medical Services Booth #832

2401 E Street, NW Washington, DC 20522-0102 202.663.1646

https://careers.state.gov/

Psychiatrists in the U.S. Department of State's Bureau of Medical Services work as part of a team to safeguard and promote the health and well-being of U.S. diplomats and their family members posted abroad. Stop by our booth to talk with us about opportunities for ABPN Board-certified psychiatrists in Washington DC and abroad.

UCSF-Fresno

Booth #721

4441 E. Kings Canyon Road Fresno, CA 93702 559.430.5667 www.fresno.ucsf.edu

UCSF Fresno is a branch campus of the UCSF School of Medicine. Established in 1975, UCSF Fresno is located in Fresno, California's fifth largest city. UCSF Fresno is focused on improving health in the Golden State and its San Joaquin Valley through medical education, patient care, research, and community partnerships.

Universal Health Services, Inc. Booth #433

367 Gulph Road King of Prussia, PA 19406 610.382.4417 www.uhsinc.com

Universal Health Services, Inc. (UHS) is the largest facilities-based behavioral health provider in the country. The Behavioral Health Division operates through subsidiaries in over 230 facilities nationwide offering services that touch more than 460,000 lives each year—from youth and adult programs to dedicated services for military personnel and their families. UHS is recruiting psychiatrists nationwide for practice opportunity positions at our behavioral health facilities.

Valant Booth #536

600 Stewart Street, #326 Seattle, WA 98101 1.888.774.0532 www.valant.com

You improve lives. We make your practice thrive. Valant provides the tools you need to automate and enhance patient engagement, outcomes measurement, and revenue. With an intuitive workflow and easy to use dashboards and reports, get more sleep knowing you are using the best practices for effective practice management. No matter the size of your patient load, software should not get in your way. Our streamlined clinical tools and integrated practice management features help keep you organized without slowing you down.

Vanderbilt Behavioral Health Booth #213

1601 23rd Avenue South Nashville, TN 37212 615.322.2238

www.vanderbilthealth.com/ psychiatrichospital/

Vanderbilt Behavioral Health is comprised of Vanderbilt Psychiatric Hospital, a 92-bed inpatient facility; the Adult and Adolescent Partial Hospitalization Programs; the Psychiatry Outpatient Clinics; the Neuromodulation program which includes Transcranial Magnetic Stimulation (TMS) and Electroconvulsive Therapy (ECT); and the Center of Excellence which provides services for children in state custody or who are at risk of a custodial situation.

D OWN... H ER D IAGNOSIS IS?

LEARN MORE AT BOOTH 327

Not actual patient. Fictionalized for illustrative purposes. TEAM ADHD is a trademark of Supernus Pharmaceuticals, Inc. ©2019 Supernus Pharmaceuticals, Inc. All rights reserved. SPN.PIP.NB.2019-0140



.

VCU HEALTH Booth #229

PO Box 980620 Richmond, VA 23298 804.382.6981

www.vcuhealth.org

VCU Health/MCV Physicians is a dynamic academic health center located in Richmond, VA. With over 19 clinical and research departments, 900 physicians, and 600 advanced practice clinicians, we continue to grow and expand our healthcare reach throughout Virginia. We seek to improve the quality of life for our patients and physicians and through quality clinical recruitment efforts. We invite you to explore joining our ever growing institution and become a part of the future of healthcare! VCU is a recognized leader in psychiatric research and education.

WellSpan Philhaven

Booth #817

283 S. Butler Road Mt. Gretna, PA 17064 717.812.4377 https://www.wellspanphilhaven.org/

WellSpan Philhaven is central Pennsylvania's most comprehensive behavioral health organization, serving Adams, Dauphin, Lancaster, Lebanon, and York counties through 54 programs and 27 care locations. For more than 65 years, we have focused on treating the whole person—mind, body and spirit. We offer services for all ages and various levels of care, including hospitalization, day programs, outpatient counseling, and services in the home, school, and community.

Wiley Booth #429

101 Stations Landing, Suite 300 Medford, MA 02155 781.388.8361 www.wiley.com

Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment, and certification solutions help universities, societies, businesses, governments, and individuals increase the academic and professional impact of their work.

Willow Springs Center Booth #208

690 Edison Way Reno, NV 89502 775.858.3303

www.willowspringscenter.com

Opened in 1988, located in Reno, Nevada, Willow Springs is a secure, 116 bed residential treatment facility for children ages 5–17. Employing a medical model ensures a board-certified child and adolescent psychiatrist directs each child's care for serious emotional and behavioral problems. Guided by Alan Fruzzetti, PhD, recognized as one of the country's premier DBT practitioners and teachers, Willow utilizes DBT programming. Our fully adherent DBT Program is at the forefront of DBT practice and innovation. Joint Commission accredited and a TRICARE certified provider.

Wolters Kluwer Booth #220

172 W. 109th Street, Apt 5E New York, NY 10025 914.400.9964

.

www.wolterskluwer.com

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. Our solutions help to build clinical competency and improve practice so that healthcare organizations can succeed in value-based care delivery models.

Booth #315

625 Alaska Avenue Torrance, CA 90503 424.201.8800

www.wpspublish.com

A family business since 1948, WPS publishes psychological and educational assessments that accurately screen, diagnose, and treat people in need. Learn more about our new products at Booth #315: Piers-Harris 3: More than just a classroom screener of self-concept; MIGDAS-2: Description over labels—a better way to understand autism; RISE: Measure risks and strengths together. You also receive 10% OFF + FREE SHIPPING! Don't forget to enter our raffle for a free assessment kit!

AACAP Exhibit Opportunities

Don't miss the chance to connect with specific demographics within the child and adolescent psychiatry community in 2020!

Tabletop exhibits are available at the Pediatric Psychopharmacology Update Institute being placed in high-traffic areas near the coffee break or an area directly adjacent to the meeting room, providing exhibitors with the great opportunity to meet attendees. The vast majority of our attendees are practicing physicians.

For more information, please visit: http://www.aacap.org/ExhibitandSponsor or contact: AACAP Meetings and Exhibits Manager, 202.966.9574 or exhibits@aacap.org.

LIFELONG LEARNING



Lifelong Learning Module 16 is now available! Module 16: Relevant Clinical Updates for Child and Adolescent Psychiatrists

With the purchase of Module 16 you will have the opportunity to earn ABPN-approved, specialty specific CME and self-assessment credits that count toward your maintenance of certification requirements. (8 SACME credits + 30 CME credits)

You can now choose to buy an electronic only version of Module 16 or continue to buy the full print version. Members choosing to purchase the print version will also receive access to the electronic version.

SPECIAL PROMOTION-SAVE \$



Pay your 2020 membership dues when you purchase Module 16, and receive substantial savings on the Module. Visit the MOC and CME Information Center in the registration area for more details.

For questions, please contact us at CME@aacap.org.

CME and MOC Information Center

Wondering how Maintenance of Certification applies to you or have a question about the requirements? Get your recertification questions answered by AACAP's experts! For more information on what you need to do to maintain your certification in child and adolescent psychiatry, visit the CME and MOC Information Center located next to the Registration Desk (Grand Ballroom Foyer, Ballroom Level, East Tower). AACAP staff will be on hand to guide you through the Maintenance of Certification process and show you everything we're doing to help you meet your CME, self-assessment, and improvement in medical practice requirements.

Need more child and adolescent psychiatry-specific CME credits? Make sure to stop by and learn about our online learning portal, your one-stop source for educational activities that will enhance your practice in child and adolescent psychiatry. **Monday, October 14** 4:00 pm-6:00 pm

Tuesday, October 15 7:00 am–5:30 pm

Wednesday, October 16 7:00 am-5:30 pm

Thursday, October 17 7:00 am-4:30 pm

Friday, October 18 7:00 am-8:30 am 11:30 am-5:30 pm

Child and Adolescent OPPORTUNITIES IN VIRGINIA'S BLUE RIDGE MOUNTAINS

The Virginia Tech Carilion School of Medicine (VTCSOM) Department of Psychiatry and Behavioral Medicine is a strong and growing presence in regional health care. Based in Roanoke and part of the VTCSOM, we have clinical, educational and research sites throughout the region.

We are seeking child and adolescent psychiatrists to help us develop and implement our vision of an integrated research institution dedicated to extraordinary patient care and educational innovation. Positions may be filled at the assistant, associate or full professor level with opportunities for undergraduate and graduate medical education and research engagement.

For more information contact Rob Way, physician recruiter, at rjway@carilionclinic.org or 540-224-5189.

THIS IS TOMORROW'S HEALTH CARE

We are an organization where innovation happens, collaboration is expected and ideas are valued. Our mission-driven health care system is built on progress and partnerships. Our courageous team is always learning, never discouraged and forever curious. And you'll find it all in Virginia's family-friendly Blue Ridge region, whose exceptional schools, low cost of living and abundant yearround outdoor activities consistently land it among the nation's highest-rated places to live.

Here at Carilion, you can make your own path, make new discoveries and, most importantly, make a difference. **This is your tomorrow with us.**



Equal Opportunity Employer - Minorities • Females • Protected Veterans • Individuals with Disabilities • Sexual Orientation • Gender Identity

MEET THE AUTHORS

Anthony L. Rostain, MD, MA

Wednesday, October 16, 10:00 am - 11:00 am

Booth #140

The Stressed Years of Their Lives: Helping Your Kid Survive and Thrive During Their College Years

The transition from high school to college is fraught with potential roadblocks and pitfalls for parents and students alike. With campus hazards like binge drinking and sexual assault making routine headlines and the skyrocketing rate of college mental health problems, parents are rightly concerned about shipping their children off to live independently. The recent college admissions scandal has also added a new layer of anxiety about the transition to college; knowing the high stakes involved in gaining entry to elite schools adds even greater stress to an emotionally charged process. As parents and adolescent mental health experts, B. Janet Hibbs, MFT, PhD, and Anthony Rostain, MD, MA, know all too well how daunting it is to navigate this terrain. In The Stressed Years of Their Lives: Helping Your Kid Survive and Thrive During Their College Years (St. Martin's Press; On-sale: April 23, 2019) they offer a comprehensive guide to how parents can prepare themselves and their children for the mental and emotional challenges college brings and the best course of action when students need professional intervention.

Robert Root, MD

Wednesday, October 16, 1:00 pm-2:00 pm

Booth #140

Image in Mind: The Psychiatrist as Photographer: Perspectives on Culture, Landscape and the Photographic Relationship

Image in Mind: The Psychiatrist as Photographer: Perspectives on Culture, Landscape and the Photographic Relationship. The photographer and psychiatrist share, in many ways, a common sensibility. Each is profoundly interested in capturing layers of meaning—describing a certain reality of experience, both physical and emotional. What interests me as a psychiatrist also stimulates my creative focus as a photographer.

Robert S. McKelvey, MD

Thursday, October 17, 2019 2:00 pm-3:00pm

Booth #140

When A Child Dies

This book focuses on the grieving process of physicians and nurses after the death of a child patient. It is based on interviews of pediatric hospital staff, especially those working in intensive care and hematology-oncology units, where child deaths are common and staff have experience dealing with terminal illness, and with the grief of parents. It focuses on staff members' emotional reactions to the death of a young person, and on their styles of coping with the death.

Manpreet K. Singh, MD, MS

Friday, October 18, 10:00 am-11:00 am

Booth #140

Clinical Handbook for Pediatric Mood Disorders

This is the first book of its kind, a one-stop reference for psychiatrists, psychologists, trainees, allied mental health professionals, and primary care clinicians in need of an authoritative and contemporary guide to the assessment and management of childhood-onset mood disorders. It is vital that clinicians be informed about the rapid and traumatic advances in the field so that they can accurately identify mood disorders and treat them in a timely fashion. Using a developmental neuroscience lens, this book provides a foundation from which novel methods of studying the characteristics and impact of mood disorders can emerge. The book was written by experts with a remarkable breadth of clinical and teaching experience in child and adolescent psychiatry. It addresses the increasing demand for clinicians to provide evidence-based care and helps to translate neuroscience into real-world clinical practice—a must for anyone interested in understanding the earliest manifestations of mood disorders.

Victor Fornari, MD

Friday, October 18, 11:00 am-12:00 pm

Booth #140

Psychiatric Nonadherence: A Solutions-Based Approach

This book explores medical nonadherence to treatment and management of psychiatric disorders across the lifespan. Leading experts in the field, specializing in a range of mental health problems describe the impact of nonadherence in the treatment of children, adolescents, transition age youth, adults, and older adults. The book eloquently articulates the key elements of effective physicians and offers clinical pearls on professionalism, empathy, and the doctor-patient relationship—a key component to solving treatment nonadherence. This volume focuses on solutions for improved clinical outcomes, including empathy and building trust, communication skills, motivational interviewing techniques, and the use of new technology.

Psychiatric Nonadherence is an excellent resource for all clinicians who care for individuals with psychiatric illness. This timely reference will provide guidance to enhance effective treatment adherence for a wide array of medical practitioners, including child and adolescent, adult, forensic, and geriatric psychiatrists and addiction medicine specialists, primary care physicians, psychologists, and nurses.

MEET THE EDITORS

Meet the JAACAP Connect Editors Justin Schreiber, DO, MPH Anne McBride, MD

Wednesday, October 16, 2019: 12:00 pm-1:30 pm

Booth #140

JAACAP Connect Editor Justin Schreiber, DO, MPH, and Associate Editor Anne McBride, MD will be on hand to tell you about the John F. McDermott Assistant Editor-in-Residence Award and answer your questions about *Connect's* mentorship opportunities and publication experiences.

.

Meet the JAACAP Editor-in-Chief **Douglas K. Novins, MD**

Thursday, October 17, 2019: 10:15 am-11:15 am

Booth #434

JAACAP Editor-in-Chief Douglas K. Novins, MD, will be available to answer questions and share information about the past, present, and future of the *Journal*.

.

Meet the WEB Editor

Michael Houston, MD

Thursday, October 17, 2019: 11:00 am-12:00 pm

Booth #140

AACAP's website is the front line for communication with members and the public. Do you have ideas for improvement or better communication at www.aacap.org? Be sure to make time to meet AACAP's WEB Editor, J. Michael Houston, MD, and let him know how we can make the AACAP's website better for you!

THANK YOU TO OUR SPONSORS!

The American Academy of Child and Adolescent Psychiatry expresses appreciation to the following organizations for their dedication and commitment to children's mental health through their support of child and adolescent psychiatry and AACAP's Annual Meeting.

HERO Sponsor Ironshore Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc.

Annual Meeting Early Career Psychiatrist (ECP) Meet and Greet Sponsor American Professional Agency, Inc.

Annual Meeting App Sponsor American Professional Agency, Inc.

Headshot Booth Sponsor Tris Pharma, Inc.

Sidekick HERO Sponsor

.

F. Hoffmann-La Roche Ltd Sunovion Pharmaceuticals Inc.

Wingman HERO Sponsor Professional Risk Management Services, Inc. (PRMS)



JORNAY PM™ (methylphenidate hydrochloride) extended-release capsules, for oral use, CII Rx only

BRIEF SUMMARY: Consult Full Prescribing Information for Complete Product Information **IMPORTANT SAFETY INFORMATION**

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including JORNAY PM, other methylphenidate-containing

products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

INDICATIONS AND USAGE

JORNAY PM is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

DOSAGE AND ADMINISTRATION

JORNAY PM should be taken only in the evening. Adjust the timing of administration between 6:30 pm and 9:30 pm to optimize the tolerability and efficacy the next morning and throughout the day.

The recommended starting dose for patients 6 years and above is 20 mg daily in the evening. Dosage may be increased weekly in increments of 20 mg per day up to a maximum daily dose of 100 mg.

Capsules may be swallowed whole or opened and the entire contents sprinkled onto applesauce.

Do not substitute for other methylphenidate products on a milligram-per-milligram basis. CONTRAINDICATIONS

Hypersensitivity to methylphenidate or other components of JORNAY PM. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate products.

Concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of a monoamine oxidase inhibitor, because of the risk of hypertensive crisis

WARNINGS AND PRECAUTIONS

Potential for Abuse and Dependence CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines have a high potential for abuse and dependence. Assess the risk for abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.

Serious Cardiovascular Reactions Sudden death, stroke, and myocardial infarction have been reported in adults treated with CNS stimulants at recommended doses. Sudden death has been reported in pediatric patients with structural cardiac abnormalities and other serious cardiac problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, and other serious cardiac problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during treatment with JORNAY PM. Blood Pressure and Heart Rate Increases CNS stimulants may cause an increase

in blood pressure (mean increase 2 to 4 mmHg) and heart rate (mean increase 3 to 6 bpm). Individuals may have larger increases. Monitor for hypertension and tachycardia.

Psychiatric Adverse Reactions Exacerbation of Pre-existing Psychosis CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. Induction of a Manie Episode in Patients with Bipolar Disorder CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression). <u>New Psychotic or Manic Symptoms</u> CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history. If such occur, consider discontinuing JORNAY PM. In a pooled analysis of studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared with 0 in placebo-treated patients

Priapism Prolonged, painful erections, sometimes requiring surgery, have been reported with methylphenidate in both pediatric patients and adults. Priapism was not reported with drug initiation but developed after time on the drug, often after an (drug holidays or during discontinuation). Patients who develop abnormally sustained (drug holidays or during discontinuation). Patients who develop abnormally sustained or frequent, painful erections should seek immediate medical attention

Peripheral Vasculopathy, including Raynaud's Phenomenon CNS stimulants, including JORNAY PM, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.

Long-term Suppression of Growth CNS stimulants have been associated with weight loss and slowing of growth in pediatric patients. Careful follow-up of weight and height in patients ages 7 to 10 years who were randomized to either methylphenidate or placebo over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and placebo-treated patients over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth (on average, 2 cm less growth in height and 2.7 kg less growth in weight over 3 years). without evidence of growth rebound during this period. Closely monitor growth (weight and height) in children treated with CNS stimulants, including JORNAY PM. Patients not growing or gaining height or weight as expected may need their treatment interrupted.

ADVERSE REACTIONS

Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Clinical Trials Experience with Other Methylphenidate Products in Children, Adolescents, and Adults with ADHD Commonly reported (≥2% of the methylphenidate group and at least twice the rate of the placebo group) adverse reactions from placebo-controlled trials of methylphenidate products include: appetite decreased, weight decreased, nausea, abdominal pain, dyspepsia, dry mouth, vomiting, insomnia, anxiety, nervousness, restlessness, affect lability, agitation, irritability, dizziness, vertigo, tremor, blurred vision, blood pressure increased, heart rate increased, tachycardia, palpitations, Vision, blood pressure increased, nearr rate increased, tachycardia, palpitations, hyperhidrosis, and pyrexia. <u>Clinical Trials Experience</u> with JORNAY PM in Pediatric <u>Patients (6 to 12 years) with ADHD</u> The safety of JORNAY PM was evaluated in 280 patients (6 to 12 years of age) who participated in two controlled clinical studies of patients with ADHD. Study 1, conducted in pediatric patients 6 to 12 years of age, was comprised of a 6-week open-label dose-optimization phase in which all patients received JORNAY PM (n=125; mean dose 50 mg), followed by a 1-week, double-blind contended bence in which activate were reademized to continue JORNAY PM. blind controlled phase in which patients were randomized to continue JORNAY PM (n=65) or switch to placebo (n=54). During the open-label JORNAY PM treatment phase, adverse reactions reported in >5% of patients included: any insomnia (41%), decreased appetite (27%), affect lability (22%), headache (19%), upper respiratory tract infection (17%), upper abdominal pain (9%), nausea or vomiting (9%), increased diastolic blood pressure (8%), tachycardia (7%), and irritability (6%). Three patients discontinued treatment because of affect lability, panic attacks, and agitation and aggression. Because of the trial design (6-week open-label active treatment phase followed by a 1-week, randomized, double-blind, placebo-controlled withdrawal), the adverse reaction rates described in the double-blind phase are lower than expected in clinical practice. No difference occurred in the incidence of adverse reactions In clinical practice. No onreferice occurred in the incidence of adverse reactions between JORNAY PM and placebo during the 1-week, double-blind, placebo-controlled phase. Study 2 was a 3-week, placebo-controlled study of JORNAY PM (n=81; mean dose 52 mg) in pediatric patients 6 to 12 years. *Most Common Adverse Reactions* (incidence of \geq 5% and at a rate at least twice placebo): any insomnia, decreased appetite, headache, vomiting, nausea, psychomotor hyperactivity, and affect lability or mood swings. One patient in the JORNAY PM group discontinued from the study due to mood swings. Table 1 provides the incidence of adverse reactions reported in Study 2 (incidence of 2% or more and at least twice placebo) among pediatric patients 6 to 12 years in a 3-week clinical trial.

Table 1: Adverse Reactions Occurring in ≥2% of JORNAY PM-treated Pediatric Patients and Greater than Placebo in a 3-Week ADHD Study (Study 2)

Body Organ System	Adverse Reaction	JORNAY PM (N=81)	Placebo (N=80)
Psychiatric	Any insomnia	33%	9%
disorders	Initial insomnia	14%	5%
	Middle insomnia	11%	4%
	Terminal insomnia	11%	1%
	Insomnia, not specified	4%	1%
	Affect lability/Mood swings	6%	1%
Metabolism and nutrition disorders	Decreased appetite	19%	4%
Nervous system	Headache	10%	5%
disorders	Psychomotor hyperactivity	5%	1%
Cardiovascular	Blood pressure diastolic increased	7%	4%
Gastrointestinal	Vomiting	9%	0%
disorders	Nausea	6%	0%
Infections and	Nasopharyngitis	3%	1%
infestations	Pharyngitis streptococcal	3%	0%
Injury, poisioning and procedural complications	Contusion	3%	0%
Musculoskeletal and procedural complications	Back pain	3%	0%
Skin and subcutaneous tissue disorders	Rash	2%	0%

Postmarketing Experience The following adverse reactions have been identified during postapproval use of methylphenidate products. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders: Pancytopenia, Thrombocytopenia, Thrombocytopenic purpura

Cardiac Disorders: Angina pectoris, Bradycardia, Extrasystole, Supraventricular tachycardia, Ventricular extrasystole

Eye Disorders: Diplopia, Mydriasis, Visual impairment

General Disorders: Chest pain, Chest discomfort, Hyperpyrexia

Immune System Disorders: Hypersensitivity reactions such as Angioedema

Anaphylactic reactions, Auricular swelling, Bullous conditions, Exfoliative conditions, Urticarias, Pruritus, Rashes, Eruptions, and Exanthemas

Investigations: Alkaline phosphatase increased, Bilirubin increased, Hepatic enzyme increased, Platelet count decreased, White blood cell count abnormal, Severe hepatic injury

Musculoskeletal, Connective Tissue and Bone Disorders: Arthralgia, Myalgia, Muscle twitching, Rhabdomyolysis

Nervous System Disorders: Convulsion, Grand mal convulsion, Dyskinesia, Serotonin syndrome in combination with serotonergic drugs

Psychiatric Disorders: Disorientation, Hallucination, Hallucination auditory, Hallucination visual, Libido changes, Mania

Urogenital System: Priapism

Skin and Subcutaneous Tissue Disorders: Alopecia, Erythema Vascular Disorders: Raynaud's phenomenon

DRUG INTERACTIONS

MAO Inhibitors Do not administer JORNAY PM concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment. Concomitant use of MAO inhibitors and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.

USE IN SPECIFIC POPULATIONS

Pregnancy Risk Summary Published studies and postmarketing reports on methylphenidate use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. No teratogenic effects were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2 and 9 times the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m² basis, respectively. However, spina bifida was observed in rabbits at a dose 31 times the MRHD given to adolescents. A decrease in pup body weight was observed in a pre- and post-natal development study with oral administration of a the basid to basid the web throughout presengent and basis. of methylphenidate to rats throughout pregnancy and lactation at doses 3.5 times the MRHD given to adolescents. The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.

Clinical Considerations Fetal/Neonatal Adverse Reactions CNS stimulant medications, such as JORNAY PM, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers. Data Human Data A limited number of pregnancies have been reported in published observational studies and postmarketing reports describing methylphenidate use during pregnancy. Due to the small number of methylphenidate-exposed pregnancies with known outcomes, these data cannot definitely establish or exclude any drug-associated risk during pregnancy. Animal Data In studies conducted in rats and rabbits, methylphenidate was administered orally at doses of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Teratogenic effects (increased incidence of fetal spina bifida) were observed in rabbits at the highest dose, which is approximately 31 times the MRHD of 100 mg/day given to adolescents on a mg/m² basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (9 times the MRHD given to adolescents on a mg/m² basis). There was no evidence of specific teratogenic activity in rats, although increased incidences of fetal skeletal variations were seen at the birdent does load (6 times the MPUE) given to adolescente an emp(m² basis). at the highest dose level (6 times the MRHD given to adolescents on a mg/m² basis, which is also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (2 times the MRHD given to adolescents on a mg/m² basis). Lactation <u>Risk Summary</u> Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. However, long-term neurodevelopmental effects on infants from CNS stimulant exposure are unknown. The devlopmental and health benefits of breastfeeding should be considered along with the mother's clinical need for JORNAY PM and any potential adverse effects on the breastfed infant from JORNAY PM or from the underlying maternal condition. Clinical Considerations Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain. Pediatric Use The safety and effectiveness of JORNAY PM in pediatric patients less than 6 years have not been established. The safety and effectiveness of JORNAY PM have been established in pediatric patients ages 6 to 17 years in two adequate and well-controlled clinical studies in pediatric patients 6 to 12 years, pharmacokinetic data in adults, and safety information from other methylphenidate-containing products. The long-term efficacy of methylphenidate in pediatric patients has not been established. Long-Term Suppression of Growth Growth should be monitored during

treatment with stimulants, including JORNAY PM. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted. <u>Juvenile Animal Toxicity Data</u> Rats treated with methylphenidate early Interrupted. <u>dury line Alimia rotacity Data</u> Rats treated with menyphenidate early in the postnatal period through sexual maturation demonstrated a decrease in spontaneous locomotor activity in adulthood. A deficit in acquisition of a specific learning task was observed in females only. The doses at which these findings were observed are at least 2.5 times the MRHD of 100 mg/day given to children on a mg/m² basis. In a study conducted in young rats, methylphenidate was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal Day 7) and continuing through sexual maturity (postnatal week 10). When these animals were tested as adults (postnatal weeks 13-14), decreased spontaneous locomotor activity was observed in males and females reviously treated with \geq 50 mg/kg/day (approximately \geq 2.5 times the MRHD of 100 mg/day given to children on a mg/m² basis), and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dose (5 times the MRHD of 100 mg/day given to children on a mg/m² basis). The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (0.25 times the MRHD of 100 mg/day given to children on a mg/m² basis). The clinical significance of the long-term behavioral effects observed in rats is unknown.

Geriatric Use JORNAY PM has not been studied in patients older than 65 years of age.

DRUG ABUSE AND DEPENDENCE

Controlled Substance JORNAY PM contains methylphenidate, a Schedule II controlled substance.

Abuse CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse. Abuse is characterized by impaired control over drug use, compulsive use, continued use despite harm, and craving. Signs and symptoms of CNS stimulant abuse include increased heart rate, respiratory rate, blood pressure, and/or sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss of coordination, tremors, flushed skin, vomiting, and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed. Abusers of CNS stimulants may chew, snort, inject, or use other unapproved routes of administration, which can result in overdose and death. To reduce the abuse of CNS stimulants including JORNAY PM, assess the risk of abuse prior to prescribing. After prescribing, keep careful prescription records, educate patients and their families about abuse and on proper storage and disposal of CNS stimulants, monitor for signs of abuse while on therapy, and re-evaluate the need for JORNAY PM use.

Dependence Tolerance Tolerance (a state of adaptation in which exposure to a drug results in a reduction of the drug's desired and/or undesired effects over time) can occur during chronic therapy with CNS stimulants including JORNAY PM. Dependence Physical dependence (a state of adaptation manifested by a withdrawal syndrome produced by abrupt cessation, rapid dose reduction, or administration of an antagonist) can occur in patients treated with CNS stimulants, including JORNAY PM. Withdrawal symptoms after abrupt cessation following prolonged high-dosage administration of CNS stimulants include: dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.

OVERDOSAGE

Signs and Symptoms Signs and symptoms of acute methylphenidate overdose, resulting principally from overstimulation of the CNS and from excessive sympathomimetic effects, may include the following: nausea, vomiting, diarrhea, restlessness, anxiety, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, hypotension, tachypnea, mydriasis, dryness of mucous membranes, and rhabdomyolysis.

Management of Overdose Consult with a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice on the management of overdosage with methylphenidate. Provide supportive care, including close medical supervision and monitoring. Treatment should consist of those general measures employed in the management of overdosage with any drug. Consider the possibility of multiple drug overdosages. Ensure an adequate airway oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. Use supportive and symptomatic measures.

© 2019 Ironshore Pharmaceuticals Inc. All rights reserved. IP000365 07/19



A novel, once-daily treatment option for patients with ADHD 6 years and older

Now Available

jornay

20ma

40ma

methylphenidate HCl () extended-release capsules

60mq

80ma

100mg

The first and only ADHD stimulant dosed in the evening

Help patients wake up ready for the day

When dosed in the evening, the delayed-release and extended-release technology of JORNAY PM enables the drug to be delivered in the early morning—and it lasts throughout the day

Visit booth #133 and JORNAYpm-pro.com to learn more about JORNAY PM

Indication and Important Safety Information

INDICATION

JORNAY PM is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including JORNAY PM, other methylphenidatecontaining products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

CONTRAINDICATIONS

- Known hypersensitivity to methylphenidate or other components of JORNAY PM. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate products.
- Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days because of the risk of hypertensive crisis.

WARNINGS AND PRECAUTIONS

- Serious Cardiovascular Reactions: Sudden death, stroke, and myocardial infarction have been reported in adults treated with CNS stimulants at recommended doses. Sudden death has been reported in pediatric patients with structural cardiac abnormalities and other serious heart problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmias, coronary artery disease, and other serious cardiac problems.
- *Blood Pressure and Heart Rate Increases:* CNS stimulants may cause an increase in blood pressure and heart rate. Monitor all patients for hypertension and tachycardia.
- Psychiatric Adverse Reactions: CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychiatric disorder and may induce a manic or mixed episode in patients with bipolar disorder. In patients with no prior history of psychotic illness or mania, CNS stimulants, at recommended doses, may cause psychotic or manic symptoms.

- *Priapism:* Prolonged and painful erections, sometimes requiring intervention, have been reported with methylphenidate products in both pediatric and adult patients. Priapism has also appeared during a period of drug withdrawal. Immediate medical attention should be sought if signs or symptoms of prolonged penile erections or priapism are observed.
- Peripheral Vasculopathy, including Raynaud's Phenomenon: CNS stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Careful observation for digital changes is necessary during treatment with ADHD stimulants.
- Long-Term Suppression of Growth: CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Monitor height and weight at appropriate intervals in pediatric patients.

ADVERSE REACTIONS

- Based on accumulated data from other methylphenidate products, the most common (>5% and twice the rate of placebo) adverse reactions for pediatric patients and adults are: appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, and blood pressure increased.
- Additional adverse reactions (≥5% and twice the rate of placebo) in pediatric patients 6 to 12 years treated with JORNAY PM: headache, psychomotor hyperactivity, and mood swings.

PREGNANCY AND LACTATION

- CNS stimulant medications, such as JORNAY PM, can cause vasoconstriction and thereby decrease placental perfusion.
- The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for JORNAY PM and any potential adverse effects on the breastfed infant from JORNAY PM or from the underlying maternal condition. Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain.

Please see additional safety information in the Brief Summary of Prescribing Information for JORNAY PM on adjacent pages.

© 2019 Ironshore Pharmaceuticals Inc. All rights reserved. IP000310 07/19

